Jean Philippe Spano

Summary

Country: France

Publications

  1. ncbi request reprint Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives
    J P Spano
    SOMPS, Groupe Hospitalier Pitie Salpetriere, Universite Pierre et Marie Curie, 47 Boulevard de l Hopital, 75013 Paris, France
    Ann Oncol 16:189-94. 2005
  2. ncbi request reprint [HPV and cancer]
    Jean Philippe Spano
    Departement d Oncologie Medicale, Groupe Hospitalier Pitie Salpetriere, Universite Pierre et Marie Curie, Paris VI, 47 bd de l Hopital, 73013 Paris
    Bull Cancer 92:59-64. 2005
  3. ncbi request reprint Hibernoma, an uncommon tumor as a differential diagnosis of liposarcoma of the thigh
    J P Spano
    Medical Oncology Department, Salpetriere Hospital, 47 Boulevard de l Hopital, 75651 Paris, France
    Anticancer Res 20:4803-4. 2000
  4. ncbi request reprint Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
    Jean Philippe Spano
    Hopital de la Pitie Salpetriere, Paris, France
    Lancet 371:2101-8. 2008
  5. doi request reprint AIDS-related malignancies: state of the art and therapeutic challenges
    Jean Philippe Spano
    Pitie Salpetriere Hospital, Department of Medical Oncology, 47 Blvd de l Hopital, 75013 Paris, France
    J Clin Oncol 26:4834-42. 2008
  6. ncbi request reprint [Cyclooxygenase 2 inhibitors and lung carcinoma]
    Jean Philippe Spano
    Hopital Pitie Salpetriere, Departement d Oncologie Medicale, Bd de l Hopital, 75013 Paris
    Bull Cancer 91:S109-12. 2004
  7. ncbi request reprint Impact of EGFR expression on colorectal cancer patient prognosis and survival
    J P Spano
    Departement d Oncologie Medicale, Hopital Pitie Salpetriere, Paris, France
    Ann Oncol 16:102-8. 2005
  8. ncbi request reprint [Cyclooxygenase 2 inhibitors and lung carcinoma]
    Jean Philippe Spano
    Hopital Pitie Salpetriere, Departement d Oncologie Medicale, Bd de l Hopital, 75013 Paris
    Bull Cancer 91:S109-12. 2004
  9. doi request reprint Lung cancer and renal insufficiency: prevalence and anticancer drug issues
    Vincent Launay-Vacher
    Department of Nephrology, Pr Deray, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Lung 187:69-74. 2009
  10. doi request reprint [Renal insufficiency and breast cancer]
    Philippe Beuzeboc
    Institut Curie, département oncologie médicale, Paris, France
    Bull Cancer 99:309-15. 2012

Collaborators

Detail Information

Publications73

  1. ncbi request reprint Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives
    J P Spano
    SOMPS, Groupe Hospitalier Pitie Salpetriere, Universite Pierre et Marie Curie, 47 Boulevard de l Hopital, 75013 Paris, France
    Ann Oncol 16:189-94. 2005
    ....
  2. ncbi request reprint [HPV and cancer]
    Jean Philippe Spano
    Departement d Oncologie Medicale, Groupe Hospitalier Pitie Salpetriere, Universite Pierre et Marie Curie, Paris VI, 47 bd de l Hopital, 73013 Paris
    Bull Cancer 92:59-64. 2005
    ....
  3. ncbi request reprint Hibernoma, an uncommon tumor as a differential diagnosis of liposarcoma of the thigh
    J P Spano
    Medical Oncology Department, Salpetriere Hospital, 47 Boulevard de l Hopital, 75651 Paris, France
    Anticancer Res 20:4803-4. 2000
    ..Our report presents a case of hibernoma of the thigh whose the diagnosis initially suggested that it was a mixed liposarcoma with myxoid and well differentiated components...
  4. ncbi request reprint Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
    Jean Philippe Spano
    Hopital de la Pitie Salpetriere, Paris, France
    Lancet 371:2101-8. 2008
    ..The aim of this study was to assess the safety and efficacy of gemcitabine plus axitinib versus gemcitabine alone...
  5. doi request reprint AIDS-related malignancies: state of the art and therapeutic challenges
    Jean Philippe Spano
    Pitie Salpetriere Hospital, Department of Medical Oncology, 47 Blvd de l Hopital, 75013 Paris, France
    J Clin Oncol 26:4834-42. 2008
    ..Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review...
  6. ncbi request reprint [Cyclooxygenase 2 inhibitors and lung carcinoma]
    Jean Philippe Spano
    Hopital Pitie Salpetriere, Departement d Oncologie Medicale, Bd de l Hopital, 75013 Paris
    Bull Cancer 91:S109-12. 2004
    ..Several in vivo studies have already shown that Cox2 specific inhibitors (celecoxib, rofecoxib) have anti-tumor activity and clinical trials using Cox2 inhibitors are currently ongoing in patients with NSCLC...
  7. ncbi request reprint Impact of EGFR expression on colorectal cancer patient prognosis and survival
    J P Spano
    Departement d Oncologie Medicale, Hopital Pitie Salpetriere, Paris, France
    Ann Oncol 16:102-8. 2005
    ..The aim of this study was to evaluate EGFR immunohistochemical reactivity in CRC biopsies, and to analyze its relationship with various histological and clinical characteristics and survival...
  8. ncbi request reprint [Cyclooxygenase 2 inhibitors and lung carcinoma]
    Jean Philippe Spano
    Hopital Pitie Salpetriere, Departement d Oncologie Medicale, Bd de l Hopital, 75013 Paris
    Bull Cancer 91:S109-12. 2004
    ..Several in vivo studies have already shown that Cox2 specific inhibitors (celecoxib, rofecoxib) have anti-tumor activity and clinical trials using Cox2 inhibitors are currently ongoing in patients with NSCLC...
  9. doi request reprint Lung cancer and renal insufficiency: prevalence and anticancer drug issues
    Vincent Launay-Vacher
    Department of Nephrology, Pr Deray, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Lung 187:69-74. 2009
    ..Lung cancer patients often present with anemia, which was not associated with the presence of RI...
  10. doi request reprint [Renal insufficiency and breast cancer]
    Philippe Beuzeboc
    Institut Curie, département oncologie médicale, Paris, France
    Bull Cancer 99:309-15. 2012
    ..In case of renal insufficiency, some other treatments such biphosphonates IV, capecitabin and platin salts need drug dosage adjustment or interruption...
  11. doi request reprint Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues
    Vincent Launay-Vacher
    Department of Nephrology, Hopital Pitie Salpetriere, Paris, France
    Breast Cancer Res Treat 124:745-53. 2010
    ..Both issues seem to be slightly but significantly more important in patients with bone metastases as compared to patients with a non-metastatic disease...
  12. doi request reprint Drug management of prostate cancer: prevalence and consequences of renal insufficiency
    Vincent Launay-Vacher
    Department of Nephrology Pr Deray, Hopital Pitie Salpetriere, Paris, France
    Clin Genitourin Cancer 7:E83-9. 2009
    ..A national multicenter study from 15 cancer centers in France analyzed IRMA data on patients with prostate cancer...
  13. doi request reprint Breast cancer among HIV infected individuals from the ONCOVIH study, in France: therapeutic implications
    Jean Philippe Spano
    AP HP, Groupe Hospitalier Pitie Salpetriere, Département d Oncologie Médicale du Prof David Khayat, 47 Boulevard de l Hopital, Paris, France
    Eur J Cancer 48:3335-41. 2012
    ..The cross-sectional ONCOVIH study prospectively enrolled HIV-infected adults and children with newly diagnosed malignancies in France in 2006...
  14. ncbi request reprint An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients
    Roger Mouawad
    AP HP, Medical Oncology Department, Salpetriere Hospital, Paris, France
    Melanoma Res 16:335-40. 2006
    ..These findings imply a better understanding of EGF-R and IL-6 cross-talk function in melanoma...
  15. ncbi request reprint [Targeted therapy: what does it mean? A physician point of view]
    Jean Philippe Spano
    Universite Pierre et Marie Curie, Departement d Oncologie Medicale, GH Pitié Salpétrière, 47 Boulevard de l Hopital, 75013 Paris
    Bull Cancer 94:F111-4. 2007
    ....
  16. doi request reprint Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer
    Jean Philippe Spano
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Invest New Drugs 30:1531-9. 2012
    ..The safety and pharmacokinetics of axitinib in combination with gemcitabine in patients with advanced pancreatic cancer was evaluated in the phase I portion of this trial. The randomized phase II portion was reported separately...
  17. ncbi request reprint [Aromatase inhibitors in adjuvant setting in breast cancer]
    Jean Philippe Spano
    Groupe Hospitalier Pitie Salpetriere, 43 bd de l Hôpital, 75013 Paris
    Bull Cancer 91:S239-43. 2004
    ..One of the main issues using the third generation of IA is their long-term side effects, especially bone turnover and lipid metabolism...
  18. ncbi request reprint Cyclooxygenase-2 as a target for anticancer drug development
    Jean Baptiste Meric
    Service d Oncologie Medicale, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Crit Rev Oncol Hematol 59:51-64. 2006
    ..Hence, we can state that targeting the COX-2 pathway is a promising strategy in the prevention and treatment of solid tumors. Ongoing trials are expected to answer - at least partly - the remaining questions concerning COX-2 and cancer...
  19. ncbi request reprint [EGF receptors in colorectal cancers]
    Jean Philippe Spano
    Service d Oncologie Medicale, Groupe Hospitalier Pitie Salpetriere, Boulevard de l Hopital, 75013 Paris
    Bull Cancer 94:F171-6. 2007
    ..Other anti-EGFR antibodies as well as small molecules inhibiting tyrosine kinase activity are currently explored in gastro-intestinal oncology...
  20. doi request reprint Treatment for metastatic malignant melanoma: old drugs and new strategies
    Roger Mouawad
    AP HP, Salpetriere Hospital, University of Pierre and Marie Curie Paris 6, Medical Oncology Department, 47 Boulevard de l Hopital, Paris, France
    Crit Rev Oncol Hematol 74:27-39. 2010
    ..An overview of established chemotherapies and immunotherapies, followed by a summary of trials testing the potential combination and new agent are explored...
  21. doi request reprint [Small HER2-positive breast cancer: which prognosis and which adjuvant treatment?]
    Anthony Goncalves
    Institut Paoli Calmettes, Oncologie Médicale, 232, boulevard Sainte Marguerite, 13009 Marseille, France, Inserm U1068, CNRS U7258, Aix Marseille Universite, Centre de Recherche en Cancerologie de Marseille, 27, boulevard Lei Roure, 13009 Marseille, France
    Bull Cancer 100:847-56. 2013
    ....
  22. doi request reprint [Protein kinases C: a new cytoplasmic target]
    Stephane Vignot
    Service d Oncologie Medicale, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Bull Cancer 95:683-9. 2008
    ..Although understanding of the role of PKC in tumor development is still incomplete, different agents are currently evaluated. This review discusses the available data, with special emphasis on clinical outcomes...
  23. ncbi request reprint [Non-AIDS-defining malignancies in HIV patients: clinical features and perspectives]
    Jean Philippe Spano
    Departement d Oncologie Medicale, GH Pitié Salpétrière, AP HP, Paris, France
    Bull Cancer 93:37-42. 2006
    ..These recommendations might be the fruit of a new networking between HIV specialists and oncologists and of an improving knowledge of the pathogenesis and clinical features of these AIDS non-defining tumors...
  24. ncbi request reprint Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Olivier Rixe
    Service d Oncologie, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    Bull Cancer 92:E1-6. 2005
    ..Given the feasibility of this pilot study, sequential chemotherapy concept should be investigated with newer cisplatin-based regimens using this approach in larger prospective studies...
  25. ncbi request reprint Lung cancer in patients with HIV Infection and review of the literature
    Jean Philippe Spano
    Pitie Salpetriere Hospital, Department of Medical Oncology, bld de I Hopital, 75013 Paris, France
    Med Oncol 21:109-15. 2004
    ..The improved survival of patients since the use of highly active antiretroviral treatments has lead to the reporting of non-AIDS defining tumors, such as lung cancer...
  26. doi request reprint Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions
    Jean Philippe Spano
    Departement d Oncologie Medicale, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    Oncologist 13:27-32. 2008
    ..e., starting treatment at an Hb level of 10-11 g/dl rather than waiting for Hb to fall to <10 g/dl) is associated with a faster achievement of an optimal Hb level, a lower transfusion requirement, and a maintained quality of life...
  27. doi request reprint Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study
    David Khayat
    Medical Oncology Department, Hospital Pitié Salpêtrière, Paris, France
    Eur J Cancer 49:790-7. 2013
    ....
  28. doi request reprint Electrolyte disorders related to EGFR-targeting drugs
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Crit Rev Oncol Hematol 73:213-9. 2010
    ..This is explained by elective tubular expression of renal EGF/EGFR. In this paper, we focus on electrolyte disorders related to anti-EGFR treatment and discuss the tubular involvement of these drugs based on their renal expression...
  29. doi request reprint VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Eur J Cancer 46:439-48. 2010
    ..Periodic monitoring of urinary protein should be carried out in anti-VEGF-treated patients and patients showing proteinuria need special referral to nephrologists...
  30. ncbi request reprint Cetuximab plus irinotecan in refractory colorectal cancer patients
    Marian Gil Delgado
    Groupe Hospitalier Pitie Salpetriere, Paris Cedex 13, France
    Expert Rev Anticancer Ther 7:407-13. 2007
    ..The evaluation of other combinations either with oxaliplatin or capecitabine, is ongoing, with preliminary reports of promising activity...
  31. ncbi request reprint Which Patients may benefit from the use of a decision support system to improve compliance of physician decisions with clinical practice guidelines: a case study with breast cancer involving data mining
    Brigitte Seroussi
    UPMC, UFR de Medecine, Sorbonne Universités, Paris, France
    Stud Health Technol Inform 192:534-8. 2013
    ..EPs associated with non-compliant decisions when the system is not used are associated with compliance when the system is used except in clinical situations where evidence is lacking. ..
  32. doi request reprint Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers
    Stephane Vignot
    Service d Oncologie Medicale, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Crit Rev Oncol Hematol 84:301-13. 2012
    ....
  33. doi request reprint Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists
    Stephane Ederhy
    Saint Antoine Hospital and University Pierre et Marie Curie VI, Paris, France
    Crit Rev Oncol Hematol 80:369-79. 2011
    ....
  34. doi request reprint Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?
    Nicolas Magne
    Department of Medical Oncology, Hopital Pitie Salpetriere, Paris, France
    Crit Rev Oncol Hematol 76:186-95. 2010
    ..The incorporation of new biomarkers or modalities for assessment of cardiac function may also become necessary to detect cardiac toxicity at earliest stage...
  35. doi request reprint Old and new serological biomarkers in melanoma: where we are in 2009
    Roger Mouawad
    AP HP, Medical Oncology Department, Salpetriere Hospital, University of Pierre and Marie Curie, Paris, France
    Melanoma Res 20:67-76. 2010
    ....
  36. ncbi request reprint [The interest of radiotherapy in cancer of the rectum]
    Jean Philippe Spano
    Hopital Avicenne, Departement d Oncologie Medicale, Bobigny 93
    Presse Med 32:315-22. 2003
    ..This depends on the initial TNM stage and the surgical technique. In order to optimally improve local control and survival of the patients, radiotherapy has become an unavoidable adjuvant treatment in specific situations...
  37. ncbi request reprint Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma
    J P Spano
    Department of Oncology, Avicenne Hospital, Bobigny, France
    Med Oncol 20:87-93. 2003
    ..Our data suggest that an aromatase inhibitor may be an effective treatment for ESS. Furthermore, routine ER and PR analyses could be useful to predict the response to hormonal therapy in ESS...
  38. ncbi request reprint Factors predictive of disease progression and death in AIDS-related Kaposi's sarcoma
    J P Spano
    Hopital Pitie Salpetriere, Service d Oncologie Médicale SOMPS, Paris, France
    HIV Med 1:232-7. 2000
    ..The natural history of Kaposi's sarcoma (KS) is poorly documented. We attempted to identify factors predictive of progression and survival in HIV-infected patients with KS and CD4+ cell counts greater than 100/microL...
  39. ncbi request reprint Nasopharyngeal carcinomas: an update
    J P Spano
    Avicenne Hospital, Department of Oncology, 125 rue de Stalingrad, 93000 Bobigny, France
    Eur J Cancer 39:2121-35. 2003
    ..The purpose of this article is to review the current knowledge in terms of the epidemiology, biology, prognosis, management and outcome of patients with NPC...
  40. ncbi request reprint Resistance to human epidermal growth factor receptor type 2-targeted therapies
    Jean Christophe Théry
    Department of Medical Oncology, Pitie Salpetriere Hospital, Paris, France Electronic address
    Eur J Cancer 50:892-901. 2014
    ..These strategies may include the establishment of predictive markers, exploration of combination therapies and modulation of nodal targets. ..
  41. ncbi request reprint [Anemia and cancer]
    Jean Philippe Spano
    Departement d Oncologie Medicale, Groupe Hospitalier Pitie Salpetriere, Boulevard de l Hopital, 75 013 Paris
    Bull Cancer 92:428. 2005
  42. ncbi request reprint Proteasome inhibition: a new approach for the treatment of malignancies
    Jean Philippe Spano
    Departement d Oncologie Medicale, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    Bull Cancer 92:E61-6, 945-52. 2005
    ..This review provides a summary of the rationale for using proteasome inhibitors and an update on available and ongoing clinical studies involving human malignancies...
  43. ncbi request reprint [Neoadjuvant endocrine therapy for breast cancer: an overview]
    Julien Domont
    Institut Curie, Departement de Radiotherapie, Paris, France
    Bull Cancer 91:55-62. 2004
    ..Therefore, clinical and histologic assessments of response brings essential informations about the breast cancer hormonal sensitivity, but may also be predictor of the future (adjuvant or metastatic) treatment responsiveness...
  44. ncbi request reprint Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives
    Joseph Gligorov
    Medical Oncology Department, CancerEst, Tenon Hospital, Paris, France
    Crit Rev Oncol Hematol 64:115-28. 2007
    ..Several controlled trials as first- or second-line therapy have started recently and over the next few years we should learn whether this approach will provide significant gains in efficacy...
  45. ncbi request reprint [Non-AIDS-related malignancies: prognostic and treatment]
    Jean Philippe Spano
    Hopital Avicenne, Departement d Oncologie Medicale, 125, rue de Stalingrad, 93000 Bobigny, France
    Bull Cancer 90:413-8. 2003
    ..The goal of this chapter is to describe the clinical and histological pattern of these malignant tumors, and to propose therapeutic guidelines for HIV patients with cancer...
  46. doi request reprint GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
    Jean Philippe Spano
    Medical Oncology Department, GH Pitié Salpétrière, Universite Paris 6, Paris, France
    Med Oncol 29:1421-8. 2012
    ..However, this retrospective data on a small sample size are considered preliminary and needs to be evaluated prospectively in a higher number of patients in a clinical trial...
  47. doi request reprint Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome
    Roger Mouawad
    AP HP, Salpetriere Hospital, University of Pierre and Marie Curie Paris 6, Laboratory of the Medical Oncology Department, 47 Boulevard de l Hopital, 75013 Paris, France
    Eur J Cancer 45:1407-14. 2009
    ....
  48. doi request reprint Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab
    A Barbier
    Département d anatomopathologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Bull Cancer 97:E9-E15. 2010
    ..The aim of the study was to correlate the expression of a panel of molecular markers between primary CRC samples and metastases...
  49. ncbi request reprint Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome
    J P Spano
    SOMPS, Pitie Salpetriere Hospital, Paris, France
    Ann Oncol 15:613-7. 2004
    ..In the present study, we evaluated CXCR4 expression in non-small-cell lung cancer (NSCLC) and the relationship between CXCR4 expression and the prognosis of stage I disease...
  50. ncbi request reprint Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours
    Clémence Hollande
    Academic Department of Oncology, University Paris VI, Paris, France
    BJU Int 113:574-80. 2014
    ..To evaluate the impact of 'hereditary-like' status in upper tract urothelial carcinoma (UTUC) on the survival of patients who have undergone radical nephroureterectomy (RNU) and adjuvant chemotherapy...
  51. ncbi request reprint Accuracy of clinical data entry when using a computerized decision support system: a case study with OncoDoc2
    Brigitte Seroussi
    UPMC, UFR de Medecine, Paris, France
    Stud Health Technol Inform 180:472-6. 2012
    ..8% (without CDSS) to 87.3% (with CDSS). Although this increase is lowered because of N- navigations (compliance rates are respectively 95% and 80% for N+ and N- navigations), the benefits of HIT outweighted its disadvantages in our study...
  52. pmc Current targeted therapies in breast cancer: clinical applications in the elderly woman
    Jean Philippe Spano
    Groupe Hospitalier de la Pitié Salpêtrière, Département d Oncologie Médicale du Prof David Khayat, Paris, France
    Oncologist 16:1144-53. 2011
    ..Future recommendations for the treatment of elderly women with breast cancer should include a multidisciplinary approach and a global geriatric assessment before treatment with anti-HER-2 therapy or bevacizumab...
  53. doi request reprint Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study
    Vincent Launay-Vacher
    Department of Nephrology, Hopital Pitie Salpetriere, Paris, France
    Crit Rev Oncol Hematol 70:124-33. 2009
    ..Anticancer drugs used may be nephrotoxic or need dosage adjustment in a high number of cases...
  54. ncbi request reprint Temsirolimus-induced glomerulopathy
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Oncology 76:170-2. 2009
    ..Kidney biopsy revealed ischemic glomeruli and focal segmental glomerulosclerosis lesion. Proteinuria level decreased to 2.80 g per day two weeks after temsirolimus withdrawal. Clinicians should be aware to this complication...
  55. doi request reprint Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer
    Jean Philippe Spano
    Medical Oncology Department, Pitie Salpetriere Hospital, APHP, University of Paris 6, Paris, France
    Crit Rev Oncol Hematol 66:21-30. 2008
    ..Since most available data come from retrospective studies, there is a need to validate these results in prospective trials...
  56. doi request reprint Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer
    M Bouchahda
    Hopital Paul Brousse, Villejuif, Paris, France
    Crit Rev Oncol Hematol 67:255-62. 2008
    ..Few data are available from clinical trials for elderly patients receiving cetuximab...
  57. pmc Breast cancer affects both the hippocampus volume and the episodic autobiographical memory retrieval
    Loretxu Bergouignan
    CNRS USR 3246, CR Icm, Pitie Salpetriere Hospital, Paris, France
    PLoS ONE 6:e25349. 2011
    ..This exception may be due to the fact that, consequently to the cancer experience as such, this population might already be characterized by a reduced hippocampus with an episodic autobiographical memory deficit...
  58. doi request reprint Management of hypertension in angiogenesis inhibitor-treated patients
    H Izzedine
    Department of Nephrology, La Pitie Salpetriere Hospital, Paris, France
    Ann Oncol 20:807-15. 2009
    ..Knowledge of this clinical toxicity and/or therapeutic target or novel biomarker of drug activity can aid clinicians choosing the optimal and least toxic regimen suitable for an individual patient...
  59. ncbi request reprint [Gemcitabine and pemetrexed update]
    Jean Philippe Spano
    Bull Cancer 94:S83. 2007
  60. ncbi request reprint [Gemcitabine and breast cancer]
    Benjamin Besse
    Departement de Medecine, Institut Gustave Roussy, 94805 Villejuif
    Bull Cancer 89:S107-14. 2002
    ..Several phase III trials are in progress in Europe and in the USA. Final judgment on the contribution of gemcitabine will not be made until the results of these further studies become available...
  61. ncbi request reprint [EGFR-targeted therapies: what's new?]
    Stephane Vignot
    Service d Oncologie Medicale, Hopital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris
    Bull Cancer 93:13-8. 2006
    ..Finally, a presentation is done about possible predictive factors for a relevant use of these molecules in the future...
  62. ncbi request reprint Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC
    Ken Andre Olaussen
    CEA DSV DRR LRO, 18 route du Panorama, 92265 Fontenay aux Roses, France
    Anticancer Res 23:4885-90. 2003
    ..2%). Here, we also report that the level of PTEN protein expression is not an independent prognostic marker in early-stage NSCLC...
  63. ncbi request reprint Telomeres and telomerase as targets for anticancer drug development
    Ken Andre Olaussen
    Laboratory of Radiobiology and Oncology, DSV DRR LRO, CEA, Fontenay aux Roses, France
    Crit Rev Oncol Hematol 57:191-214. 2006
    ..However, we discuss some of the main limits for these approaches of antitumour drug development and why significant work remains before a clinically useful drug can be proposed to patients...
  64. ncbi request reprint Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer
    Benjamin Besse
    Institut Gustave Roussy, Division of Cancer Medicine, Villejuif, France
    Clin Cancer Res 10:5665-9. 2004
    ..Thus, the subcellular location of Apaf-1 (but not that of p53 or Hsp70) constitutes an accurate prognostic factor for overall survival in NSCLC...
  65. ncbi request reprint [Prognostic value of EGFR in colorectal cancer]
    Stephane Vignot
    Service d Oncologie Medicale, Hopital Saint Louis, 1, Av Claude Vellefaux, 75010 Paris
    Bull Cancer 92:S13-6. 2005
    ..The finding of a profile linked to worse prognosis could allow pointing out tumours where EGFR overexpression is associated to disease progression and therefore could help to define EGFR- inhibitors' indications in colorectal cancer...
  66. ncbi request reprint [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor]
    Nicolas Mounier
    Service d Onco Hématologie, hôpital de l Archet 1, 151, Route de Saint Antoine de Ginestiere, 06202 Nice
    Bull Cancer 93:1139-43. 2006
    ..As a whole these data define temsirolimus as a promising new drug. Current and further developments are based on its association with chemotherapy in a concomitant or sequential way...
  67. ncbi request reprint Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma
    Eric Rosenthal
    Service d Hématologie Clinique and G E R C B T, hôpital Archet 1, 151 route de Saint Antoine de Ginistière, 06200 Nice, France
    Am J Clin Oncol 25:57-9. 2002
    ..Our study confirms that daunorubicin is effective in patients with advanced KS. Daunorubicin is well tolerated over the long term in association with HAART...
  68. ncbi request reprint EGFR/VEGF signalling pathway in colorectal cancer: the way we are!
    Jean Philippe Spano
    Bull Cancer 92:S3-4. 2005
  69. ncbi request reprint JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications
    Jean Philippe Spano
    Eur J Cancer 42:2668-70. 2006
  70. ncbi request reprint Chemoprevention of lung cancer
    Stephane Vignot
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Recent Results Cancer Res 166:145-65. 2005
    ..New chemoprevention trials are planned with collaborative efforts of researchers involved in fundamental or clinical studies...
  71. ncbi request reprint [Non-metastatic intrahepatic cholestasis associated with bronchial adenocarcinoma]
    Pierre Saintigny
    Service d Oncologie Medicale, Hopital Avicenne, AP HP, 93009 Bobigny
    Ann Med Interne (Paris) 154:171-5. 2003
    ..We describe here a patient with lung adenocarcinoma which led to paraneoplastic cholestasis. We discuss the diagnosis and review the literature, emphasizing the pathophysiology of Stauffer's syndrome...
  72. ncbi request reprint [Cannabis and cancer]
    Stephane Vignot
    Association d études et de recherche des Internes en oncologie, 24, rue Victor Massé, 75009 Paris
    Bull Cancer 93:163-70. 2006
    ..This review of the literature analyses these questions with special concern on the carcinogenic role of cannabis, the potential antitumor effect of cannabinoids and the place of THC and its derivatives for supportive care in cancerology...
  73. ncbi request reprint [Anemia and colorectal cancer]
    Stephane Vignot
    Service d Oncologie Medicale, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris
    Bull Cancer 92:432-8. 2005
    ..Anemia associated with advanced colorectal cancers provides the same interest as for any metastatic tumor, as quality of life of patients is correlated to the hemoglobin's level...